Seminar: "Rapid and highly sensitive detection of fluorescently-labeled biosensors"

Apr 13, 2018
10 a.m.
Green Hall, Room 0120

Amos Danielli will present.

Abstract: Sensitive and rapid detection of fluorescently-labeled biosensors at low concentrations is crucial in many biological and medical applications. Fluorescently-labeled biosensors are widely used in detection of specific DNA sequences or proteins, as well as in investigation of protein-protein interactions. In particular, detection of sequence-specific nucleic acids is important in pathogen detection and gene expression analysis, and the detection of proteins that serve as biomarkers is useful in diagnosis of diseases. For example, when a patient suffers a heart attack, increasing amounts of a cardiac protein (troponin) are slowly released to the patient’s blood. Rapid detection of troponin levels early after the onset of symptoms significantly reduces the time required to diagnose or rule out heart attack. Today, most high sensitivity laboratory devices cannot provide results in a clinically relevant time frame, and, unfortunately, present point-of-care (POC) devices are substantially less sensitive than laboratory assays. To reap the benefits of improved patient care and reduced costs through prompt diagnostics, new platforms must be developed. Recently, we discovered that by combining magnetic and fluorescent labeling of target analytes and then applying an alternating external magnetic field gradient, we can significantly increase the sensitivity of fluorescence detection. The external alternating magnetic field condenses the targets to a small volume and imposes on them a periodic motion, which enables separation of the background signal from the oscillating target signal without complex sample preparation. Here, I will demonstrate the use of this technology, named Magnetic Modulation Biosensing (MMB), in detecting proteins, antibodies, specific DNA sequences, and protein-protein interactions. I will also present the MMB advantages and limitations compared to state-of-the-art technologies, such as Luminex-200 and Euroimmun ELISA.